SALT LAKE CITY--Myriad Genetic Laboratories, Inc. and the American
College of Surgeons (ACS) have announced a long-term study that
will follow the outcomes of patients currently undergoing BRCA1
genetic analysis for breast and ovarian cancer susceptibility.
The study--ACS-Myriad BRCA1 Longitudinal study (AMBLS)--will address
two major questions: Which BRCA1 mutations are strongly penetrant
(have a strong correlation to the risk of getting the disease),
and what is the likely clinical outcome after medical and surgical
Sloan-Kettering to Administer
Administered for the ACS by the Sloan-Kettering Institute for
Cancer Research (SKI) in New York, the study will be under the
coordination of Ken Offit, MD, MPH, chief, Clinical Genetic Service,
Department of Human Genetics, and Pat Borgan, MD, chief, Breast
Service, Department of Surgery, at SKI, and Dr. Samuel Wells,
vice chair of the ACS board.
The AMBLS study will utilize Myriad's BRACone genetic analysis
test and multicenter patient database to obtain mutation incidence
and clinical data. Investigators will fill out a baseline registration
form for consenting patients. At the patient's annual exam, investigators
will provide follow-up information concerning the patient's status.
To ensure confidentiality, codes linking the database to patient
identifiers will reside solely in the hands of the patient's local